T cells need to be activated by dendritic cells (DCs) before they will attack a tumor. Sumimoto et al. (page 1651) now show that a common skin cancer mutation interferes with this pathway, thus helping the tumor to evade the body\'s immune defenses.

Activating point mutations in the serine-threonine kinase BRAF are found in 66% of all malignant melanomas. The resulting activation of BRAF-ERK-MAPK signaling---the primary pathway involved in growth factor--induced proliferation of melanocytes---immortalizes the cells.

One BRAF mutation (BRAF^V600E^), according to Sumimoto and colleagues, also prompts human tumor cells to produce vascular endothelial growth factor, interleukin (IL)-6 and IL-10, all of which inhibit the production of proinflammatory cytokines by dendritic cells (DCs).

Disabling DCs, and thereby preventing their activation of tumor-specific T cells, is a popular tumor cell trick. Indeed, activation of the transcription factor STAT3---common among hematopoietic and epithelial cancers---triggers the production of a similar array of DC-inhibiting cytokines. In that model, blocking STAT3 in tumor-bearing mice resulted in T cell attack on the tumor. Whether blocking BRAF will have the same reinvigorating effect on melanoma-specific T cells awaits the development of an animal model.

Interfering with BRAF signaling might enhance immune-activating antitumor therapies, such as DC immunization or T cell immunotherapy, as activation of the cells induced by these approaches might otherwise be blunted by the tumor\'s suppressive output. ![](jem_iti_end.jpg)
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